Review finds no class-wide antiseizure effect for GLP-1 agonists in epilepsy
Authors mapped 21 preclinical papers and eight human studies, reporting null and pro-seizure results in absence epilepsy models alongside broader neuroprotection signals.
PR
By Priya Raman · Science Reporter
Sep 8 20:00 ETSource: International journal of molecular sciences
The wire
- 01A critical narrative review in International Journal of Molecular Sciences separated antiseizure, neuroprotective and disease-modifying claims across 21 preclinical publications and eight human studies identified through 6 August 2026.
- 02Clinicians fielding questions about semaglutide and seizures have a structured evidence map: the authors say semaglutide is directly under-tested in epilepsy and human data are largely observational or safety-oriented.
- 03Authors call for chronic epilepsy studies with longitudinal video-EEG, post-insult designs controlling insult severity, and linked target-engagement work; durable disease modification remains suggestive, not established.
From the source
Read at pubmed.ncbi.nlm.nih.govGLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification
International journal of molecular sciences · 2026 Sep 9 · Gorgul YA, Zaitsev AV et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42794466/
